OncoSec Medical Appoints Dr. Holbrook Kohrt to Scientific Advisory Board
August 06 2014 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
ImmunoPulse DNA-based intratumoral cancer immunotherapy, has
appointed Dr. Holbrook Kohrt, M.D., Ph.D., to the company’s
Scientific Advisory Board. Dr. Kohrt joins a growing panel of
distinguished experts and renowned thought leaders, and will
contribute his considerable expertise to the company as it works to
advance an expanding immuno-oncology pipeline.
Holbrook E. Kohrt, M.D., Ph.D., is an Assistant Professor at
Stanford Cancer Institute, and currently investigates novel
therapeutic strategies to enhance anti-tumor immunity. Dr. Kohrt
attended Stanford University Medical School as the Baxter
Foundation Scholar, Howard Hughes Scholar, and American Society of
Hematology Research Fellow. During this time he developed,
validated, and nationally implemented a nomogram for risk
prediction in early stage breast cancer.
Dr. Kohrt trained in Internal Medicine at Stanford University
through the Clinical Investigator Pathway and completed fellowship
in Hematology and Oncology at Stanford with a research focus on
preclinical models of novel immunomodulatory antibodies. He
received his Ph.D. in clinical trial design and tumor immunology
from Stanford. Most notably, Dr. Kohrt along with Dr. Ron Levy at
Stanford have been the academic leaders in the advancement of
intratumoral immuno-oncology therapies. Recently, they conducted a
Phase I/II clinical trial using CG-enriched oligodeoxynucleotide
(CpG), a ligand for the Toll-like receptor 9 (TLR9) in
non-Hodgkin’s lymphoma. As well, they have demonstrated that
intratumoral administration of the checkpoint inhibitor,
anti-CTLA-4 antibody, is a safe and effective route of therapy in
mice, demonstrating both local and systemic responses.
“We are extremely excited to have Dr. Kohrt join our scientific
advisory board”, said Punit Dhillon, President and CEO. “Holbrook’s
background and experience will be invaluable as we not only move
our ImmunoPulse program forward into later stage clinical
development, but he and the rest of the SAB, will also be integral
in keeping our intratumoral immunotherapy platform at the cutting
edge of scientific advances.”
Dr. Kohrt said, “OncoSec’s DNA-based intratumoral immunotherapy
technology has the potential to address an important unmet medical
need in cancer immunotherapy. I am pleased to help guide OncoSec’s
scientific team as it continues to target difficult diseases and
advance new intratumoral therapeutic targets for the treatment of
cancer.”
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma,
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024